Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

@article{Lepola2004DoED,
  title={Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder},
  author={U. Lepola and A. Wade and H. Andersen},
  journal={International Clinical Psychopharmacology},
  year={2004},
  volume={19},
  pages={149-155}
}
  • U. Lepola, A. Wade, H. Andersen
  • Published 2004
  • Psychology, Medicine
  • International Clinical Psychopharmacology
  • Escitalopram is the S-enantiomer of citalopram. In this study, we compared the efficacy of equivalent dosages of escitalopram and citalopram in the treatment of moderate to severe major depressive disorder (MDD), based on data from two, pooled, randomized, double-blind, placebo-controlled studies of escitalopram in which citalopram was the active reference. The primary efficacy parameter was the mean change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) total score… CONTINUE READING
    Escitalopram versus citalopram: the surprising role of the R-enantiomer
    • 218
    • Highly Influenced
    Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    • 80
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 36 REFERENCES
    A RATING SCALE FOR DEPRESSION
    • 25,472
    • PDF
    A new depression scale designed to be sensitive to change.
    • 10,015
    Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    • 331
    • Highly Influential
    Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care
    • 156
    Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
    • 98
    Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine
    • 304